Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis Holding AG (NASDAQ:OCS) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 29,100 shares, an increase of 127.3% from the January 31st total of 12,800 shares. Based on an average daily trading volume, of 70,000 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the shares of the stock are sold short.

Oculis Stock Down 0.5 %

Shares of Oculis stock traded down $0.10 during trading on Friday, reaching $19.58. The company had a trading volume of 38,424 shares, compared to its average volume of 93,908. The company has a market cap of $793.07 million, a price-to-earnings ratio of -10.15 and a beta of -0.24. Oculis has a fifty-two week low of $10.55 and a fifty-two week high of $23.08. The firm’s fifty day moving average is $20.58 and its 200-day moving average is $16.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02.

Analyst Ratings Changes

Several research analysts have recently issued reports on OCS shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Oculis in a research note on Monday, January 6th. Chardan Capital restated a “buy” rating and set a $28.00 target price on shares of Oculis in a research report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $28.80.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Oculis during the 4th quarter valued at $389,000. Bank of America Corp DE raised its holdings in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after acquiring an additional 10,667 shares in the last quarter. Bellevue Group AG acquired a new stake in shares of Oculis during the 4th quarter valued at about $170,000. XTX Topco Ltd bought a new stake in Oculis in the fourth quarter valued at $225,000. Finally, Geode Capital Management LLC grew its stake in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after buying an additional 1,800 shares during the last quarter. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.